A group of citizens visit the La Marató project at the Research Institute

Dr. Gemma Vilahur, from the Research Group on Molecular and Therapeutic Pathology of Atherothrombotic and Ischemic Diseases of the São Paulo Research Institute, explained the project “Intravenous administration of a modified HMG-CoA reductase inhibitor as a promising cardioprotective strategy in ischemic heart disease: Unlocking its cardioprotective benefits and mechanisms of action, in a highly transferable pre-clinical animal model”, funded by the Marathon, to a group of interested citizens.

This website uses cookies to improve the browsing experience and perform analytical tasks. If you continue browsing, we understand that you agree our cookies policy. More information